Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

219.75 +0.10 (+0.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cidara Therapeutics, Inc. - Common Stock

News headline image
Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara... 
Via TheNewswire.com
Topics Regulatory Compliance
News headline image
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara... 
Via TheNewswire.com
Topics Regulatory Compliance
News headline image
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
From 5AM Venture Management, LLC
Via GlobeNewswire
News headline image
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
News headline image
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
News headline image
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
From Cidara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
From Cidara Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
From Cidara Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.